The launch time and approval progress of eflornithine (IWILFIN) in China

Eflornithine (IWILFIN) is a targeted therapy drug that is an ornithine decarboxylase (ODC) inhibitor. It inhibits the proliferation and growth of tumor cells by specifically inhibiting ODC activity and interfering with polyamine metabolism pathways. Polyamines play a key role in tumor cell division and metastasis, and ODC is the rate-limiting enzyme for polyamine synthesis. Inhibiting its activity can effectively reduce the risk of tumor recurrence, especially for patients with high-risk neuroblastoma (HRNB).

Clinical studies have shown that IWILFIN can be used as adjuvant treatment for adult and pediatric patients with high-risk neuroblastoma to reduce the rate of disease recurrence. For HRNB patients, traditional treatment options include surgery, chemotherapy and radiotherapy, but the recurrence rate is still high. IWILFINBy targeting the polyamine metabolism pathway, IWILFIN provides patients with an additional mechanism to prevent relapse, thereby improving long-term prognosis.

During use, IWILFIN is generally administered in the form of oral tablets, and its dosage and course of treatment need to be individually adjusted based on the patient's age, weight, and kidney and liver function. The drug can be used in combination with conventional chemotherapy or surgical treatment during the adjuvant treatment phase, but hematological indicators and liver and kidney functions need to be strictly monitored to ensure safety.

In general, IWILFIN intervenes in polyamine metabolism by inhibiting ODC activity, providing a new adjuvant treatment strategy for high-risk neuroblastoma patients. Its characteristics are strong targeting and the ability to reduce the risk of recurrence, which is of great significance for improving the long-term survival rate of HRNB patients. With further in-depth clinical research in the future, IWILFIN is expected to become an important part of the treatment of high-risk neuroblastoma.

Reference link:https://www.drugs.com